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ABSTRACT
STAT5A and STAT5B proteins belong to the family of
signal transducers and activators of transcription.
They are encoded by two separate genes with 91%
identity in their amino acid sequences. Despite their
high degree of conservation, STAT5A and STAT5B
exert non-redundant functions, resulting at least in
part from differences in target gene activation. To
better characterize the differential contribution of
STAT5A and STAT5B in gene regulation, we per-
formed single or double knockdown of STAT5A and
STAT5B using small interfering RNA. Subsequent
gene expression profiling and RT-qPCR analyses of
IL-3-stimulated Ba/F3-b cells led to the identification
of putative novel STAT5 target genes. Chromatin
immunoprecipitation assays analyzing the corre-
sponding gene loci identified unusual STAT5 binding
sites compared to conventional STAT5 responsive
elements. Some of the STAT5 targets identified are
upregulated in several human cancers, suggesting
that they might represent potential oncogenes in
STAT5-associated malignancies.
INTRODUCTION
The STAT (signal transducers and activators of transcrip-
tion) family of transcription factors comprises seven
members (STAT1, STAT2, STAT3, STAT4, STAT5A,
STAT5B and STAT6), which are essential mediators of
cytokine, growth factor and hormone responses. STAT
proteins play important functions in a variety of path-
ways, from innate and acquired immunity to cell prolif-
eration, diﬀerentiation and survival [reviewed in reference
(1)]. Accordingly, inappropriate activation of STATs, in
particular of STAT1, STAT3 and STAT5, is associated
with a wide variety of human cancers and diseases, and
constitutively activated STAT signaling directly contri-
butes to oncogenesis (2,3).
As with other STAT family members, STAT5 is mostly
present in the cytoplasm as latent monomers. Upon
stimulation by a broad spectrum of cytokines (4), STAT5
is recruited to the cytokine receptor through an interaction
between STAT5 SH2 domain and a speciﬁc receptor
phosphotyrosine residue. STAT5 is then phosphorylated
on a conserved carboxy-terminal tyrosine, leading to its
dissociation from the receptor and dimer formation.
Dimerization is mediated by a reciprocal SH2-phospho-
tyrosine interaction between two phospho-STAT5 mole-
cules, and is a prerequisite for DNA binding activity (5).
Although STAT5 monomers can shuttle between the
cytoplasm and the nucleus, STAT5 dimers are actively
translocated to and retained in the nucleus where they
bind to speciﬁc DNA binding sites and activate tran-
scription (1,6,7). Transcriptional activation by STAT5
involves recruitment of the coactivators CBP/p300 (8) and
NCoA-1 (9), and requires a deacetylase activity (10,11).
STAT5A and STAT5B proteins are encoded by two
distinct but chromosomally linked genes, and share 91%
identity in their amino acid sequence. Interestingly, the
most divergence is found within the carboxy-terminal
phosphotyrosyl tail and transactivation domain (4).
STAT5A and STAT5B exert redundant yet distinct func-
tions, as revealed by single and double knockout mice
studies (12,13). Thus, while STAT5A is essential for
prolactin-dependent mammary gland development and
lactogenesis (14,15), STAT5B mediates the sexual dimor-
phic eﬀects of growth hormone (15–17). In the immune
system, both STAT5A and STAT5B regulate IL-2 signal-
ing, with a stronger contribution of STAT5B through
regulation of both IL-2Ra and IL-2Rb gene expression,
while STAT5A only regulates IL-2-induced IL-2Ra
expression (15,18,19).
Multiple factors contribute to the non-redundant
functions of STAT5A and STAT5B. Diﬀerences in
STAT5A/B mRNA levels (20–22), activation by tyrosine-
and serine-phosphorylation (23–27), and nucleocytoplas-
mic shuttling (7,28,29), all regulating STAT5A and
STAT5B availability in the nucleus have been reported.
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(STAT5A:STAT5A, STAT5B:STAT5B), heterodimers
(STAT5A:STAT5B), as well as tetramers represent a
major level of diﬀerential regulation of transcription by
STAT5A and STAT5B. Although the DNA binding
sequences of the various STAT proteins are very similar
(TTC N3–4 GAA), clear diﬀerences in DNA binding
speciﬁcities have been described (30,31). While both
STAT5A and STAT5B are required for induction of the
human Cis gene, they show distinct speciﬁcities in binding
to the 4 STAT5 binding sites located in the proximal
promoter in vitro (32). Subtle amino acid diﬀerences within
the DNA binding domain of STAT5A and STAT5B have
been shown to play a role in diﬀerential DNA binding
speciﬁcities (33). STAT5 tetramerization represents
another main level of transcriptional regulation. STAT5
binding sites are often found in tandem in gene regulatory
regions, allowing cooperative binding through interactions
involving the N-terminal domains of two neighboring
STAT5 dimers (34–36). In vitro, STAT5A molecules bind
DNA preferentially as tetramers, whereas STAT5B
molecules form dimeric complexes (32,37). Interestingly,
tetramerization is tightly coupled to tyrosine dephosphor-
ylation and nuclear accumulation of STAT5 (38), suggest-
ing that diﬀerential tetramerization of STAT5A and
STAT5B may inﬂuence the downstream prolongation or
attenuation of the STAT5 response of a particular target
gene in vivo. In support of this hypothesis, STAT5A and
STAT5B show distinct kinetics and dynamics of DNA
binding in vivo (39).
Beside DNA binding speciﬁcity, diﬀerential transcrip-
tional activation by STAT5A and STAT5B might possibly
involve recruitment of speciﬁc cofactors through their
divergent carboxy-terminal domain, although STAT5A-
and STAT5B-speciﬁc cofactors have not been described
thus far. Finally, diﬀerential attenuation mechanisms
(dephosphorylation by phosphatases, degradation via the
proteasome-dependent pathway, naturally occurring
dominant negative truncated STAT5 variants, negative
feedback loop by the Cis/SOCS proteins) might also
participate in diﬀerential regulation by STAT5A and
STAT5B (22,40–42).
As predicted from the non-redundancy of STAT5A
and STAT5B functions in vivo, a diﬀerential contribution
of STAT5A and STAT5B in the progression of various
cancers has been reported. For example, while STAT5A
activation has been associated with mammary cancer
progression (43), STAT5B activation has been more speci-
ﬁcally associated with squamous cell carcinoma of thehead
and neck (SCCHN) tumorigenesis (44,45). This implies
that there are distinct downstream target genes acting as
oncogenes that are speciﬁcally induced by either STAT5A
or STAT5B.
Identiﬁcation of novel STAT5-dependent oncogenes, a
better characterization of the respective contribution of
STAT5A and STAT5B in their regulation, and the identi-
ﬁcation of the level of diﬀerential regulation (activation,
nuclear translocation, DNA binding, transcription) might
oﬀer novel possibilities for speciﬁc therapeutic interven-
tion in STAT5-associated cancers.
With this in mind, we conducted a gene expression
proﬁling study on IL-3-stimulated Ba/F3-b cells following
small interfering RNA (siRNA)-mediated knockdown of
both STAT5A and STAT5B expression. New STAT5-
regulated genes were identiﬁed. The selective knockdown
of STAT5A or STAT5B demonstrated that these proteins
diﬀerentially inﬂuence the expression proﬁles of these
genes in response to IL-3 stimulation. Speciﬁc STAT5
binding sites were identiﬁed within some of these genes
using chromatin immunoprecipitation (ChIP), unveiling
conventional as well as unusual binding site sequences and
locations compared to STAT5 binding elements reported
so far. Interestingly, some of the novel STAT5 targets are
overexpressed in several cancers, suggesting that they
might represent putative oncogenes.
MATERIALS AND METHODS
Cells
The IL-3-dependent murine proB cell line Ba/F3-b was
grown in RPMI 1640 containing 10% FBS and 10ng/ml
IL-3 (10,46). For cytokine stimulation, cells were washed
in RPMI 1640 and rested for 6h in RPMI 1640 containing
10% FBS before addition of 10ng/ml IL-3 for the
indicated times.
Proteinanalysis
Cells were lysed and analyzed by western blot as pre-
viously described (10,46), using antibodies speciﬁc for
STAT5A, STAT5B and STAT3 (sc-1081, sc-835 and
sc-483 respectively, Santa Cruz Biotechnology, Santa
Cruz, CA, USA).
mRNAanalysis byRT-qPCR
RNA isolation, cDNAs synthesis (RT) and real-time
quantitative PCR (qPCR) expression analysis were per-
formed as previously described (10,46). Data were normal-
ized to S9 ribosomal mRNAs and expressed as relative
mRNA levels. Murine-speciﬁc forward and reverse real-
time PCR primers used in this study are as follows.
STAT5A: CGCTGGACTCCATGCTTCTC and GACG
TGGGCTCCTTACACTGA; STAT5B: GGACTCCGTC
CTTGATACCG andTCCATCGTGTCTTCCAGATCG;
STAT3: AATGGAAATTGCCCGGATC and AGGCG
AGACTCTTCCCACAG; Socs-3: CCAAGAACCTACG
CATCCAGTG and CGTGGGTGGCAAAGAAAAGG;
Pim-2: TACGCCTTCTTGACTGGTTCG and CATAG
GCCGCTCAAGGACC; IL-2Rb: AGAGAAGGGTTG
GCGTAGGG and TTGTCAAAGGGATGGAAGTCG;
Heparin binding EGF-like growth factor: CGTACTC
CCTCTTGCAAATGC and GAGTCAGCCCATGACA
CCTGT; Socs-1: TTCTTGGTGCGCGACAGTC and
AAGCCATCTTCACGCTGAGC; C3ar1: CTGACCTA
CACTCACGGCCTC and CCATTGCCTAGCAGTCC
CAA; TNFRSF13b: CTGCTGTTTCTTGGTGGCCT
and AGAGTTTGCTTGTGACCCACG; Slfn2: TGTAC
AAGTGAGCGCCGCT and TGCAGGCAACTCTGGT
CTGA; Enah: TGTCAGACGCCACTCCTGATT and
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TGGGAACTCTAACC and CCCTCCATGTCCACGA
ACTC. Primers speciﬁc for the following cDNAs have
been already described: S9, Cis, c-Myc, Pim-1, Osm, Bcl-x,
p21, Id, MKP-1, IL-4Ra, Stra13, Spi2.1, Ryk, TCRg-V4
and IL-2Ra (10).
Smallinterfering RNA (siRNA)-mediated knockdown
STAT5A, STAT5B, STAT3 and ScI siRNA duplexes were
synthesized using the Silencer siRNA Construction Kit
(Ambion #1620, Austin, TX, USA), as formerly described
(46). SiRNA sequences for STAT5A, STAT5B and ScI
have been described (46). STAT3 siRNA sequence is (50–
30): AAGCAGCAGCTGAACAACATG. SiRNA were
transfected by electroporation as previously described
(46). Brieﬂy, 3.10
6 Ba/F3-b cells were transfected with a
total amount of siRNA of either 10mg [STAT5A/B double
knockdown, using 2.5mg each of a pool of four siRNAs
(46)], 8mg [STAT5A and STAT5B single knockdown, 4mg
each of STAT5A or STAT5B pool of two siRNAs (46)],
or 5mg (STAT3 knockdown), in the presence of 50U of a
FITC-labeled uptake control (Sequitur #3013, Invitrogen,
Carlsbad, CA, USA). Four hours posttransfection, FITC-
positive cells were sorted by FACS and cultured for 22h in
RPMI 1640 containing 10% FBS and 0.2ng/ml IL-3,
followed by 5h resting (RPMI 1640 containing 10% FBS)
and IL-3 stimulation (10ng/ml) for 30min and 2h. Cells
were harvested at time 0 of IL-3 stimulation for western
blot analysis and at times 0, 0.5 and 2h of IL-3
stimulation for RNA and microarray analysis. STAT5
western blot analysis following STAT5 knockdown has
been published (46).
DNA microarray analysis
Ba/F3-b cells were washed in PBS, total RNA was isolated
from unstimulated ScI siRNA-transfected Ba/F3-b cells,
and IL-3-stimulated (30min and 2h) ScI siRNA- or
STAT5A/B siRNA-transfected Ba/F3-b cells using the
RNeasy Maxi kit, including an oncolumn DNase I
treatment to eliminate genomic DNA contamination,
according to the manufacturer’s protocol (Qiagen,
Valencia, CA, USA). DNase-treated total RNA (5mg)
was synthesized into biotinylated cRNA probe using one-
cycle target labeling and IVT labeling (Aﬀymetrix, Inc.,
Santa Clara, CA, USA) according to manufacturer’s
instructions. Fifteen microgram of biotinylated cRNA
probe from each sample was hybridized onto murine
U74A, U74B, U74C Aﬀymetrix Microarray chips. The
hybridized chips were then washed using the Aﬀymetrix
GeneChip Fluidics 400 station and scanned in the
Aﬀymetrix GeneChip Scanner 3000 (Aﬀymetrix, Inc.,
Santa Clara, CA) according to manufacturer’s instruc-
tions. The quality of cRNA probe synthesis and eﬃciency
of hybridization was analyzed in the GeneChip Operating
System for each Aﬀymetrix chip once scanning was
complete. Microarray data were normalized using MAS5
and then analyzed using the Genespring (Agilent, Palo
Alto, CA, USA). Out of 36767 genes, 14553 passed our
noise and P/M/A call ﬁlters. Genes were further selected
for being stimulated at least 2-fold by IL-3 after 30min
(164 genes) and 2h (553 genes) stimulation compared to
the unstimulated cells (ScI-transfected cells). Then, IL-3
induced genes that were downregulated at least 2-fold in
the STAT5A/B siRNA-transfected cells at 30min and 2h
(12 and 29, respectively) were identiﬁed as putative
STAT5 target genes and further investigated. The data
discussed in this publication have been deposited in
NCBIs Gene Expression Omnibus (GEO, http://
www.ncbi.nlm.nih.gov/geo/) and are accessible through
GEO Series accession number GSE10389.
ChIP
STAT5 ChIP was performed on unstimulated and IL-3-
stimulated (45min) Ba/F3-b cells, using STAT5A and
STAT5B antibodies (sc-1081 and sc-835 respectively,
Santa Cruz Biotechnology, Santa Cruz, CA, USA) or no
antibody (protein A-sepharose control), and analyzed by
real-time PCR as formerly described (10,46). Data are
expressed as a percentage of input DNA. The genomic
sequence of each gene (^6000 relative to the transcription
start site up to the polyA signal) was searched for STAT5
binding sites using the Vector NTI software (Invitrogen,
Carlsbad, CA, USA). Forward and reverse real-time PCR
primers used for the mouse genomic DNA analysis are as
follows. Primers speciﬁc for STAT5 binding sites-contain-
ing regions are underlined, the others being control
primers. Cis (^184): GTCCAAAGCACTAGACGCCTG
and TTCCCGGAAGCCTCATCTT; Cis (+4200): TACC
CCTTCCAACTCTGACTGAGC and TTCCCTCCAGG
ATGTGACTGTG; IL-2Ra (^1270): GCATGATATG
ATGTGCAGTTTCTTC and TCAGGACTGGTGGTT
GGTTG; IL-2Ra (^90): AAACACTGCCCACACCTC
CT and TTTGCGGTAATTTTTCAAACCA; Spi2.1
(^1740): GCACAGTGGAAGGGAAAAGC and ACCC
ACCACATCCAACATCA; Spi2.1 (^127): AAATCAC
CCGGTCTGTCCAT and TGTTGATGCAGATAAGC
TGTGC; Socs-1 (^2100): CAACATTGCTTGGCTAA
CGG and CTGGGAAAGCTCTGGGAAGTT; Socs-1
(^1200): GCCCACCAAGGGTTAGACTGA and
TGAATTTGTGTGGCTGTGGTTG; Socs-1 (^480): GC
CCCACAGGTCTCTAGGACTA and CTTGGCAA
TCTCGACCCTTC; Socs-3 (^1235): TTTCACCTCAAT
CACCTGCTCT and TCTGAACTTTCCCGATGGTG;
Socs-3 (^345): CTGCCAGAAACCAGCCTTC and GC
CCCCAACTTCTCATTCA; Socs-3 (^95): GCACAG
CCTTTCAGTGCAGAG and GTATTTACCCGGC
CAGTACGC; C3ar1 (^3000): ATGGCAGCTCACA
ACTGTCTGT and CGTGTCTGTGGGATGGTGTC;
C3ar1 (^1850): ACACAGAGAAACCCTGCCTCA and
CTTTGGGCGCTTATTGCTCT; C3ar1 (^1620): TTGA
GAAAGTGCCTCCACCAGA and CCAAGAAA
ATGACCCACAGCC; C3ar1 (^480): TGCTTGGTA
GCAATGCCTGT and TTCTCCTGCCTCCGTCTTCT;
C3ar1 (+1380): GCCTTCAGCGAAGAGCTCAC and G
AAGAGGCTTTGTCTTGGGTACA; TNFRSF13b
(^600): TAAAGCCCTTGCCTGTGACC and GCTAT
CCCCGACAGAATGACA; TNFRSF13b (+1680): GG
AACGGCAAGATGGAAGAT and CCATGGACTTC
CCAGAAAGC; TNFRSF13b (+3780): GCAGC
TGAGTGACAGCAGTGT and CCACAGTCTCCCT
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GGCTCAC and GCCTTCTGGCTGATTTCCAC;
MKP-1 (^1700): GGCAGCAGTTCCAGCTCTTT and
GCTGTGGAGTTCTGCCCTCT; MKP-1 (+1680): TCC
CCTGCTATCCTTTGCAT and AGGGTCTGCCTCTT
GCAGTC; Osm (^226): CATCATCCTTGGGCGTGGG
GC and CGCTCCTCCTCCCGTTTTCTTCG; Osm
(+2875): CGGTCCACTACAACACCAGATGTC and
TATCCCCAGAGAAAGCCACAGC; Pim-2 (^2740):
TGATCCCAGCACTGAGGAGG and GCTGGCCTG
CAACTCAAAAG; Pim-2 (^1515): TGAGTCTTGAG
TCAACCAGTTTCTC and CGGAAACAGACACATC
CACAC; Pim-2 (^1135): GCAGCACAAATATTTCTGT
GAATGT and TCACAAGCACACAAGCACCA; Pim-2
(^545): AATTTTACCCTTCCCTGAAGAGTG and GA
TCAGGCAGCCTTTGCTC; Pim-2 (^270): CACCCCA
CCACACCAACA and TGCACGCTTCTGGGAATTC;
IL-2Rb(^5840):TGCCTTGGTCATGGTATCTGTT and
AGGGACCCAGCTGAGATAAGG; IL-2Rb (^840):
GCCCCGATGAAGATGGTAATG and AGCTT
CTGCCCTCTTGTGAAAAG; IL-2Rb (+2725): GGC
CTGAGCGATTCCTTTTC and AGGCGAGAAGCAT
CCACATC; Ryk (^4116): CCTTTTTCCAGTGGCTGT
GA and GCTGCTGCTGTCTTTTGTCG; Ryk (^2190):
AGGGGCCAATACCAGAATCAC and AGGAGAGG
AACAGCTGGAATTG; Slfn2 (^400): TATCCCCTTTC
CTGGTCCTG and GTGGATGGGAGAGGGAGTTG;
Slfn2 (+4130): CGGCTCTGTCTGTTTTCCAGG and
CCAGCAGCCTTTGCATTTTC; Slfn2 (+4680): CAAG
CATAGCCTTCCCTGAAG and ATGCAGCAGCCAA
ATCCTC; Slfn2 (+4800): TACATTGCTTTCAGCGA
AACG and GTTTGAGGGAGGAGCTCTTTGA; Slfn2
(+5040): GTACACGTGCAAATTCATCGAAG and CG
CACACACATATGCACACAC; Id (^2600): CACAGTC
TGTTCTTTGAAGTTGGTC and CCAATGCCTGAAC
CTCAGAAA; Id (^1000): CCTGGCGTCTAACGGTC
TGandACCCCCTCCCTTTCCTTTC;Id(+135):GCAG
GCCCTAGCTGTTCG and GCTCCGACAGACCAAG
TACCA; Id (+5358): GGACCAGGCGCTACTTTCC
and TGGTTCCTCCTAGTCCTGGTTT; Id (+5690): G
CTCTCAGGCATCCTGAGCT and CGATT
TGACTTTGCAGGAACC.
Cancer panel
Paired human tumor (primary melanoma and renal
tumors) and normal adjacent tissues (NAT) were obtained
from patients undergoing routine therapeutic surgery from
the following sources: Dr David Gotley of the Princess
Alexandra Tumour Tissue Bank (Woolloongabba,
Queensland Australia), Zoion Diagnostics (Hawthorne,
New York, USA), National Disease Research Interchange
(NDRI) (Philadelphia, PA, USA) and Zoion Diagnostics
(Shrewsbury, MA, USA). Normal human tissue were
obtained from patients undergoing routine surgery
[NDRI, Ardais Corporation, Lexington, MA, USA and
Cooperative Human Tissue Network (CHTN), Nashville,
TN, USA], from short hour autopsy ( 5h, Zoion
Diagnostics), and from transplant donors (Anatomical
Gift Foundation, Hanover, MD, USA). Tumor tissue was
collected for each case, and when possible matching NAT
was also collected. Each case was accompanied with a brief
clinical history, pathology report and pathological diag-
nosis. All surgical samples were frozen as quickly as
possible, typically within an hour of excision. All sample
diagnoses and staging were conﬁrmed internally by a
pathologist. This information was used to select cases, 87
melanoma cases and 35 renal cell carcinoma cases to be
studied for expression analysis. Cases excluded from the
study had either other diagnoses or large areas of necrotic
tissue, upon examination by an inhouse pathologist.
For real-time quantitative PCR analysis, total RNA
was isolated using RNA STAT-60 (Tel-Test,
Friendswood, TX, USA) according to manufacturer’s
instructions. After isopropanol precipitation, total RNA
was re-extracted with phenol:chloroform:isoamyl alcohol
(25:24:1) (Sigma Chemicals, Balcatta, Perth, Western
Australia). Total RNA (5mg) was subjected to treatment
with DNase I (Roche Molecular Biochemicals,
Indianapolis, IN, USA) according to manufacturer’s
instructions to eliminate possible genomic DNA contam-
ination, and reverse transcribed using Superscript II
(Invitrogen) according to manufacturer’s instructions.
Real-time quantitative PCR was conducted as described
above and the data were normalized to ubiquitin mRNA
levels. The human forward and reverse qPCR primers
used were as follows. C3ar1: CTGGT
GTCAGAATCATCGCAA and CATCCACAGATAGA
GCAGGCC; c-Myc: AACAGGAACTATGACCTCG
and AGCAGCTCGAATTTCTTC. The ubiquitin primers
have been described (47). Statistical analysis of tumor
expression was conducted using a Kruskal–Wallis non-
parametric test.
RESULTS
Identification of novel STAT5-regulated genes inIL-3
stimulated Ba/F3-bcells
To identify novel IL-3-inducible STAT5 target genes in
the proB cell line Ba/F3-b, we exploited an experimental
system previously described by our group (46), in which
expression of both STAT5A and STAT5B proteins
(hereafter designated STAT5A/B) was knocked down
using small interfering RNA (siRNA). Upon siRNA-
mediated knockdown, STAT5A and STAT5B mRNA and
protein levels were equally reduced by  60% [Figure 1A
and reference (46)]. Following siRNA transfection,
Ba/F3-b cells were starved from cytokine and stimulated
with IL-3 for 30min and 2h. Isolated RNAs were
hybridized on an Aﬀymetrix DNA array covering the
whole mouse genome to identify IL-3-induced genes that
were downregulated in the STAT5A/B knockdown.
After 30min of IL-3 stimulation, 164 probes were
induced by IL-3at least 2-fold, 12 of which were down-
regulated at least 2-fold in the STAT5A/B knockdown
(corresponding to 11 diﬀerent genes). Seven genes were
validated by RT-qPCR (below and data not shown). Four
are known genes (Cis, Socs-1, Heparin binding EGF-like
growth factor and Stra13) and three are unknown genes.
After 2h of IL-3 stimulation, 553 genes were induced at
least 2-fold by IL-3, 29 of which were downregulated at
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to 27 diﬀerent genes). Twenty-one genes were validated by
RT-qPCR (below and data not shown). Twelve are known
genes (including the four already identiﬁed after 30min
stimulation) and nine are unknown genes. These known
genes are shown in Table 1 with the corresponding
Aﬀymetrix data showing the fold induction by IL-3 and
the fold inhibition following STAT5A/B knockdown.
The identiﬁcation of known STAT5 target genes such as
Cis, Spi2.1 and Socs-1 (48–50) demonstrated the validity
of our experimental approach. Furthermore, Cis, Spi2.1,
Ryk and Stra13 were identiﬁed by our group in a previous
gene expression proﬁling study as inhibited by trichostatin
A (TSA), a histone deacetylase inhibitor also acting as a
potent repressor of STAT5-mediated transactivation (10).
Our microarray analysis upon STAT5A/B knockdown
thus conﬁrmed several known STAT5 targets and revealed
seven potential novel STAT5 target genes (Table 1).
STAT5 target genesare differentially regulated
by STAT5A and STAT5B
We next examined the diﬀerential contribution of
STAT5A and B proteins in the regulation of STAT5
target gene expression. Following the same strategy as
above, expression of either STAT5A or STAT5B was
speciﬁcally knocked down in Ba/F3-b cells by siRNA
transfection. Reduction in STAT5 mRNA and protein
levels upon siRNA-mediated knockdown in the single
knockdown was similar ( 60%) to that observed in the
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Figure 1. STAT5 mRNA levels in Ba/F3-b cells upon STAT5A and STAT5B double (A) and single (B) knockdown. Ba/F3-b cells were transfected
either with a non-speciﬁc siRNA (ScI), or with siRNAs speciﬁc for STAT5A (5A), STAT5B (5B) or both (5AB). Twenty-six hours later, cells were
starved for 5h and stimulated with IL-3. Cells were harvested at the indicated times, and mRNAs levels were monitored by RT-qPCR. A 60%
reduction in STAT5 mRNA levels was detected in both the single and double knockdown, with the expected speciﬁcity. Reduction in STAT5 protein
levels was veriﬁed by western blot and has been already published (46). STAT3 mRNA levels (this ﬁgure), as well as protein levels (46), remained
unaﬀected, conﬁrming the speciﬁcity of STAT5 targeting.
3806 Nucleic Acids Research, 2008, Vol. 36, No. 11double knockdown [Figure 1B and reference (46)]. In
addition to the genes shown in Table 1, our study was
broadened to additional putative STAT5 targets [derived
from our formerly described gene proﬁling analysis of
TSA sensitivity (10)] and to well-characterized STAT5
target genes (Table 2). mRNA levels upon IL-3 stimula-
tion of a total of 24 genes were evaluated and compared in
the double STAT5A/B and single STAT5A and STAT5B
knockdown cells by RT-qPCR (Figure 2 and Table 2).
Interestingly, four distinct expression patterns were
observed. First, a group of genes including Cis (Figure 2),
Socs-3, Osm, Pim-1, Pim-2, MKP-1, Stra13, IL-2Rb,
TCRg-V4 and Heparin binding EGF-like growth factor,
which were downregulated in the double knockdown were
weakly or even not aﬀected in the single knockdown
(Figure 2 and Table 2), indicating functional redundancy
between STAT5A and STAT5B proteins. A second
pattern was STAT5-regulated genes aﬀected in both
single knockdowns, although at various degrees. Genes
such as C3ar1 (Figure 2), Socs-1, TNFRSF13b, Ryk,
Slfn2 and p21, revealed an equal requirement for both
STAT5A and STAT5B (Figure 2 and Table 2), whilst
other genes showed a preferential contribution of either
STAT5A (Spi2.1) or STAT5B (IL-2Ra, IL-4Ra) (Figure 2
and Table 2). Third, Enah (Figure 2) and Lama5 genes
revealed a clear speciﬁcity toward STAT5B, while none of
the evaluated genes showed an exclusive speciﬁcity toward
STAT5A (Figure 2 and Table 2). Finally and unexpect-
edly, three known STAT5 targets (Id-1, c-Myc and Bcl-x)
remained unaﬀected in the STAT5A/B double knock-
down, and hence in the single knockdown (Figure 2 and
Table 2). To rule out that this absence of eﬀect was due to
compensatory mechanisms mediated by STAT3, the other
main STAT molecule activated in Ba/F3-b in response to
IL-3 (51,52), expression of Id-1, c-Myc and Bcl-x was
evaluated in IL-3-stimulated Ba/F3-b cells following
siRNA-mediated knockdown of STAT3 (Figure 3A and
B). While IL-3 induction of Socs-3, a well-characterized
STAT3 target (53) was repressed following STAT3
knockdown (Figure 3B), IL-3 induction of Id-1, c-Myc
and Bcl-x remained unaﬀected (Figure 3C) as was IL-3
induction of Cis, another STAT5 target (Figure 3B). This
suggests that Id-1, c-Myc and Bcl-x are not STAT3 targets
and therefore that the lack of eﬀect in the STAT5A/B
knockdown cannot be attributable to functional redun-
dancy between the two STAT molecules.
This experimental approach thus conﬁrmed that
STAT5A and STAT5B exert overlapping as well as
distinct functions in vivo at the level of transcriptional
regulation, and led to the recognition of distinct categories
of STAT5 target genes based on the diﬀerential contribu-
tion of STAT5A and STAT5B in their regulation.
STAT5is recruited at unusualsites to theC3ar1,
MKP-1 andTNFRSF13b gene loci
To address how these diﬀerences in gene expression relate
to STAT5 DNA binding in vivo, and to separate direct
STAT5 targets from genes indirectly regulated by STAT5,
ChIP was performed on a subset of the above genes.
Known STAT5 target genes with characterized (Cis, Osm,
Socs-3, Spi2.1, IL-2Ra and Id-1) or uncharacterized
(Socs-1) STAT5 binding sites and putative STAT5 targets
(MKP-1, Stra13, Pim-2, C3ar1, TNFRSF13b, Ryk, Slfn2
and IL-2Rb) were investigated. ChIP was performed on
unstimulated and IL-3-stimulated (45min) Ba/F3-b cells
using antibodies directed against STAT5A and STAT5B,
and the immunoprecipitated genomic DNA was analyzed
by real-time PCR. First, the genomic sequence (from ^
6000 relative to the transcription start site up to the polyA
signal) of each gene was scanned for the presence of
putative consensus STAT5 binding motifs (TTCNN
NGAA) as well as non-consensus motifs, and real-time
PCR primer pairs were designed to examine these regions
as well as remote control regions (10,46).
STAT5 recruitment to the known STAT5 target genes
Cis, Osm, Socs-3, Spi2.1, IL-2Ra and Id-1 was detected
at the expected position (Figure 4A and Table 2).
Additionally, we were able to identify the so far
uncharacterized STAT5 binding site of the Socs-1 gene
at position ^2100 relative to the transcription start site
(Figure 4A). No STAT5 binding could be detected by
ChIP on the Stra13, Pim-2, Ryk, Slfn2 and IL-2Rb
Table 1. IL-3 inducible genes downregulated upon STAT5A/B knockdown in Ba/F3-b cells (Aﬀymetrix array data)
Gene name Accession no. 30min 2h
Fold up Fold down Fold up Fold down
(IL-3) (5AB) (IL-3) (5AB)
1 Cytokine inducible SH2-containing protein (Cis)
a NM_009895 10.12 2.82 14.43 2.43
2 Cytokine inducible SH2-containing protein 1 (Socs-1)
a NM_009896 7.91 2.74 3.66 2.23
3 Serine (or cysteine) proteinase inhibitor (Spi2.1)
a M64085 2.71 1.99 6.24 2.59
4 Receptor-like tyrosine kinase (Ryk) L21707 1.25 1.01 4.25 3.44
5 Stimulated by retinoic acid 13 (stra13/clast5) NM_011498 3.29 2.36 5.45 2.32
6 Schlafen 2 (Sﬂn2) NM_011408 2.72 1.35 14.17 5.92
7 Serine/threonine kinase (Pim-2) L41495 1.41 1.31 5.04 2.07
8 Heparin binding epidermal growth factor-like growth factor NM_010415 4.75 2.51 7.71 2.07
9 G-protein coupled receptor; anaphylatoxin C3a receptor 1 (C3ar1) NM_009779 1.76 2.92 2.75 3.34
10 TNFRSF13b NM_021349 1.41 1.46 2.19 3.25
11 Enabled homolog (Drosophila) (enah); Mena; VASP; WASP NM_010135 0.96 1.13 2.66 2.21
12 Laminin, alpha 5 (Lama5) U37501 1.08 1.22 2.60 2.01
aKnown STAT5 targets from the literature (see text).
Nucleic Acids Research, 2008, Vol. 36, No. 11 3807Table 2. STAT5A/STAT5B relative contribution and STAT5 DNA binding characteristics on the known and novel STAT5 target genes evaluated in this study
RT-qPCR ChIP assay
Gene name Accession no. % inhibition
in 5AB KD
STAT5
binding
%o f
input
DNA
b
STAT5 binding site
c (positions
relative to tss)
References IL-3 induction
proﬁle
STAT5A or STAT5B
1 Cytokine inducible SH2-containing
protein (Cis)
a
NM_009895 59 + 6 4c. in tandem (^230/^103) (10,48), this study Early, sustained
2 Cytokine inducible SH2-containing
protein 3 (Socs-3)
a
NM_007707 54 + 3.5 2c.+1 n.c. in tandem (^345/^64) (53), this study Early, transient
3 Oncostatin M (Osm)
a D31942 59 + 4 2c. in tandem (^190/^95) (93), this study Early, transient
4 MAP kinase phosphatase 1 (MKP-1) X61940 52 + 0.4 2c. in tandem (^3450/^3414) This study Early, transient
5 Stimulated by retinoic acid 13 (stra13/clast5) NM_011498 67 ^^ [2c. ^680/^410] This study Early/late, sustained
6 Serine/threonine kinase (Pim-2) L41495 56 ^^ [4c. ^1520/^270] This study Late, sustained
7 Interleukin 2 receptor, beta (IL-2Rb) M28052 59 ^^ [1c. ^5840; 1c. +2725] This study Late, sustained
8 Heparin binding epidermal growth factor-like
growth factor
NM_010415 71 ND ND ND This study Late, sustained
9 Serine/threonine kinase (Pim-1)
a NM_008842 35 ND ND ND (10), this study Early, sustained
10 T-cell receptor gamma, variable 4 (TCRg-V4)
a NM_011558 36 ND ND ND (10), this study Late, sustained
STAT5A and STAT5B
(i) Equal contribution
11 Cytokine inducible SH2-containing
protein 1 (Socs-1)
a
NM_009896 52 + 0.6 2c.+1 n.c. in tandem
(^2095/^2061)
This study Early, transient
12 G-protein coupled receptor; anaphylatoxin
C3a receptor 1 (C3ar1)
NM_009779 91 + 1.1 7 n.c. (^2085/^1520) This study Early, sustained
13 TNFRSF13b NM_021349 86 + 3 2c. (+1662/+1735, intron 2) This study Late, sustained
14 Receptor-like tyrosine kinase (Ryk) L21707 79 ^^ [1c. ^2190; 7 n.c. ^4150/+1] This study Late, sustained
15 Schlafen 2 (Sﬂn2) NM_011408 90 ^^ [no c. in promoter; 4c. +4130/+5040] This study Late, sustained
16 p21 (WAF1/CIP1)
a NM_007669 66 ND ND ND (10), this study Early, transient
(ii) A>B
17 Serine (or cysteine) proteinase inhibitor (Spi2.1)
a M64085 85 + 0.9 1c.+1 n.c. in tandem (^127/^92) (50), this study Late, sustained
(iii) B>A
18 Interleukin 2 receptor, alpha (IL-2Ra)
a NM_008367 90 + 2.5 1c.+1 n.c. in tandem (^1268/^1240) (35), this study Late, sustained
19 Interleukin 4 receptor, alpha (IL-4Ra) M29854 62 ND ND ND (10), this study Early, sustained
STAT5B speciﬁc
20 Enabled homolog (Drosophila) (enah); Mena;
VASP; WASP
NM_010135 79 ND ND ND This study Late, sustained
21 Laminin, alpha 5 (Lama5) U37501 82 ND ND ND This study Late, sustained
?
22 Helix-loop-helix DNA binding protein
regulator (Id-1)
a
M31885 0 + 1.6 1c.+2 n.c. in tandem (+5350/+5710) (11), this study Early/late, sustained
23 Myelocytomastosis oncogene (c-Myc)
a X01023 0 ND ND ND (10), this study Early, sustained
24 Bcl-x
a L35049 0 ND ND [2c. in tandem, +386/+475, intron 1] (10,39,85), this study Late, sustained
aKnown STAT5 target genes from the literature.
bNo antibody control generated background values of 0.01–0.1% of input DNA (see also Figure 4).
cValues in square bracket indicates putative binding motifs found in the genomic sequence that showed no STAT5 binding by ChIP.
Abbreviations: c., consensus; n.c., non-consensus; ND, not determined; tss, transcription start site.
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1putative STAT5 target genes, even though consensus
STAT5 binding sites were found within the investigated
regions (Table 2). STAT5 recruitment was detected,
however, within the C3ar1, TNFRSF13b and MKP-1
genes (Figure 4B).
The sequence and position of the functional STAT5
binding elements evaluated in this study are presented in
Table 3. In all cases, STAT5 binding sites are present in
tandem of two or more consensus or/and non-consensus
motifs. While 4 out of the 10 elements analyzed were
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Figure 2. Expression of known and putative STAT5 target genes in STAT5A and STAT5B double (A) and single (B) knockdown. RNAs were
isolated from Ba/F3-b cells treated as described in Figure 1, and analyzed by RT-qPCR. Six distinct expression proﬁles could be recognized,
represented here by selected genes (see also Table 2), revealing a clear diﬀerential contribution of STAT5A and STAT5B in regulating expression of
STAT5 target genes.
Nucleic Acids Research, 2008, Vol. 36, No. 11 3809located in the proximal region of the promoter (<400bp
upstream of the transcription start site; Cis, Osm, Socs-3
and Spi2.1), as typically described for STAT5 target genes,
four were located in the distal promoter (^1200 to ^3450;
MKP-1, Socs-1, C3ar1 and IL-2Ra), one within an intron
(+1660; TNFRSF13b) and one several kilobase down-
stream of the gene (+5350; Id-1) (Table 3). The most
unforeseen ﬁnding was STAT5 recruitment at the C3ar1
distal promoter (^2085/^1520) that lacks consensus
STAT5 motifs but comprises seven non-consensus ele-
ments (Figure 4B and Table 3). The resolution of the ChIP
experiment does not, however, allow for the discrimina-
tion of the relative involvement of each motif over this
565-bp long region.
Interestingly, the potency of STAT5 DNA binding
in vivo to the various elements varied signiﬁcantly from 0.4
to 6% of input DNA (Figure 4 and Table 2). Although
these diﬀerences might reﬂect variability in antibody
accessibility, they might also reveal diﬀerences in DNA
binding aﬃnities on the various target genes in vivo.
The newly identified STAT5 targetsC3ar1, MKP-1
and TNFRSF13b are potential oncogenes
Constitutive activation of STAT5A and STAT5B has been
associated with a wide variety of human cancers,
especially hematologic malignancies (leukemia, lymphoma
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Figure 3. STAT3 and STAT5 do not have redundant functions in regulating STAT5 target gene expression in IL-3-stimulated Ba/F3-b cells. Ba/F3-b
cells were transfected with a siRNA speciﬁc for STAT3 or with a control siRNA (ScI), as described in Figure 1. (A) At the time of IL-3 stimulation, a
speciﬁc reduction in STAT3 protein levels upon STAT3 knockdown was veriﬁed by western blot using antibodies directed against STAT3 or STAT5 as a
control. (B and C) mRNA levels for STAT3, SOCS-3—a STAT3 target—and Cis, Id-1, c-Myc and Bcl-x were analyzed as described in Figures 1 and 2.
3810 Nucleic Acids Research, 2008, Vol. 36, No. 11and myeloma), as well as solid tumors such as breast
cancer, SCCHN or melanoma (2,3,45,54–58).
Our gene expression proﬁling study combined with ChIP
analysis identiﬁed three novel direct STAT5 target genes,
namely, TNFRSF13b, MKP-1 and C3ar1 raising the
possibility that overexpression of these genes in STAT5-
associated malignancies plays a role in tumorigenesis.
Interestingly, tumor necrosis factor receptor superfamily,
member 13B (TNFRSF13b) has been associated to
lymphoid and non-lymphoid malignancies and to immu-
nologic disorders (59–64), while MKP-1 (MAP kinase
phosphatase-1) has been associated to a variety of human
cancers (65–67).
C3ar1 encodes a G-protein coupled seven-
transmembrane receptor for the anaphylatoxin and
chemoattractant C3a, an important inﬂammatory media-
tor (68). C3ar1 is implicated in Th2 development and
is linked to the pathogenesis of asthma (69,70). It is
expressed in normal kidney (71) and its upregulation
is associated to the development of lupus nephritis (72).
Beside its implication in inﬂammatory diseases, C3ar1
overexpression has been recently associated to FMS-like
tyrosine kinase 3 (FLT3) D835/I836 mutants-mediated
cytogenetically normal acute myeloid leukemia (CN-
AML) (73), which is also associated to constitutive
STAT5 signaling (74–77).
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Figure 4. STAT5 recruitment in vivo on known (A) and novel (B) STAT5 target genes. Ba/F3-b cells were stimulated with IL-3 for 45min and ChIP
was performed as described in Materials and Methods section, using antibodies directed against STAT5A and STAT5B (5AB) or no antibody as a
control (^). The isolated genomic DNA was analyzed by real-time PCR using primers speciﬁc for STAT5 binding sites or control regions, as
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Nucleic Acids Research, 2008, Vol. 36, No. 11 3811To further correlate expression of C3ar1 with the
development of cancer, we monitored C3ar1 mRNA
levels on various cancer panels (Figure 5). Interestingly,
C3ar1 expression was found to be signiﬁcantly upregu-
lated in renal clear cell carcinoma (Figure 5A) and
melanoma (Figure 5B). Although activation of STAT5
signaling was shown to directly contribute to the progres-
sion of malignant melanoma (55,56,58,78), an implication
of STAT5 in renal cell carcinoma has not yet been clearly
established (2,57,79). Expression of c-Myc, an oncogene
regulated by numerous transcription factors including
STAT5, was also upregulated in renal cancer (Figure 5C).
Upregulation of c-Myc and C3ar1 was observed in 24 out
of a panel of 30 pairs (80%) of ‘normal adjacent tissue’
and ‘renal cell carcinoma’ (not shown), and their
expression correlated well in both normal and malignant
tissues (Figure 5C). The observation that the newly
identiﬁed STAT5 target gene C3ar1 is upregulated in
several cancers (AML, renal cell carcinoma and mela-
noma) some of which being clearly associated to
constitutive STAT5 signaling (AML and melanoma),
therefore, raises the possibility that C3ar1 upregulation
might play a role in tumorigenesis as a STAT5 target, and
opens the door to further investigation.
DISCUSSION
Using a gene expression proﬁling approach followed
by a ChIP analysis we were able to identify novel
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Figure 5. C3ar1, a novel STAT5 target gene, is overexpressed in (A, C)
renal cell carcinoma and (B) melanoma. Expression of C3ar1 and
c-Myc was evaluated by RT-qPCR on a panel of cDNAs samples from
various human tumors and the corresponding NAT, as well as from
normal tissues, as described in Materials and Methods section. mRNA
levels were normalized to ubiquitin mRNA levels. C3ar1 is over-
expressed in renal cell carcinomas (n=35) (A) and melanoma tumors
(n=94) (B) compared to normal tissues [renal (n=12) and skin
(n=15), respectively] and NAT [NAT renal (n=33) and NAT skin
(n=91), respectively]. P-values for the diﬀerence in medians
between tumors, normal tissues and NAT are <0.0001 by a two-
tailed non-parametric Mann-Whitney test (Graph Pad Prism).
The box represents 25–75th percentile of the data, the line represents
the median and whiskers are the minimum and maximum values.
(C) Expression of C3ar1 and c-Myc is upregulated in renal cell
carcinoma (black dots) compared to NAT (gray dots) and normal
tissues (white dots). Additionally, expression of C3ar1 and c-Myc is
correlated in renal tumor and normal tissue. The squared correlation
value, R
2 is 55%.
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Ba/F3-b cell line. Furthermore, a siRNA-mediated knock-
down of STAT5A and STAT5B proteins demonstrated a
clear functional diﬀerence between both proteins in
regulating expression of these genes in vivo.
Our microarray analysis showed that 5–7% of the IL-3
inducible genes were (directly or indirectly) regulated by
STAT5 in Ba/F3-b cells. Although this approach does not
allow us to identify all STAT5 target genes, as revealed by
the absence of eﬀect of STAT5 knockdown on some
known STAT5 targets such as c-Myc, Id-1 or Bcl-x
(Table 2), it suggests that most of the IL-3 inducible genes
are likely regulated through the MAP kinase and
PI3-Kinase pathways which are also activated in response
to IL-3 in these cells (80). Reciprocally, out of the genes
downregulated in the STAT5A/B knockdown, only 20%
were IL-3 inducible (not shown), suggesting that STAT5
may exert additional functions in regulating cytokine-
independent genes. This proposition corroborates a recent
ChIP-based study that identiﬁed STAT5 binding sites in
the vicinity of IL-3 independent genes in Ba/F3 cells (39).
Although diﬀerential transcriptional regulation by
STAT5A and STAT5B on a particular target gene has
been already described (31), our study is the ﬁrst to eval-
uate the relative contribution of STAT5A and STAT5B in
the regulation of several STAT5 target genes in vivo. Since
STAT5A and STAT5B are activated in a similar fashion
in Ba/F3-b cells in response to IL-3 (39), the diﬀerential
contribution of STAT5A and STAT5B is very likely
attributable to diﬀerences in the regulatory potential of
the two proteins, based in part on the DNA binding
activity of the various STAT5 complexes. In support of
this, STAT5 ChIP eﬃciency varied from 0.4 to 6% of input
DNA, although these values should be taken with caution
since diﬀerences in epitope availability might signiﬁcantly
contribute to the ChIP eﬃciency. These diﬀerences might
also reﬂect the distinct kinetics of STAT5A and STAT5B
DNA binding observed in vivo (39).
The analysis of the relative contribution of STAT5A
and STAT5B to the expression of a number of STAT5-
regulated genes revealed that approximately a third of
these genes showed a strict requirement for both proteins,
while a similar proportion showed redundancy between
both STAT5 proteins (Table 2). A requirement for both
STAT5A and STAT5B may suggest that transcription is
dependent on STAT5A:STAT5B heterodimers. An alter-
native explanation is that STAT5A and STAT5B homo-
dimers bind selectively to either one of tandemly arranged
binding sites, consistent with observations in vitro (32,37).
Redundancy between both STAT5 proteins suggests that
STAT5A and STAT5B homodimers are equally eﬃcient
in DNA binding and transcriptional activation of the
corresponding genes. It is likely that STAT5A:STAT5B
heterodimers play little function in that context.
Unexpectedly, IL-3-mediated induction of the Cis gene
was not preferentially aﬀected upon STAT5A knockdown
in vivo. This contradicts the in vitro data showing a clear
preference for STAT5A tetramers over STAT5B homo-
dimers (32). This demonstrates that in vivo DNA binding
activity involves other components, such as chromatin
conﬁguration, accessory regulatory elements and/or
cofactors, which are lacking in in vitro experiments.
Interestingly, some genes (Enah and Lama5) were
speciﬁcally aﬀected by the absence of one particular
STAT5 protein in vivo (Table 2), in accordance with the
non-redundancy of STAT5A and STAT5B functions
in vivo (12,13,31).
STAT5A/B gene targeting studies showed that IL-2
signaling is impaired in STAT5A/B knockout mice, due to
a diminished expression of both IL-2Ra and IL-2Rb in T
and NK cells (15,18,19). These studies suggested that
while IL-2 induction of IL-2Ra requires both STAT5A
and STAT5B, IL-2 induction of IL-2Rb preferentially
involves STAT5B (18,19). In the IL-3-stimulated proB Ba/
F3-b cell line, expression of IL-2Ra was also dependent on
both STAT5A and STAT5B, with a stronger participation
of STAT5B (Figure 2 and Table 2). However, IL-3
induction of IL-2Rb was redundantly regulated by
STAT5A and STAT5B, thus revealing a functional
diﬀerence between IL-2 and IL-3 signaling in regulating
transcription of the IL-2Rb gene. On the other hand, since
no functional STAT5 binding site was found within the
IL-2Rb gene (Table 2), a direct regulation by STAT5
remains hypothetical.
The serine/threonine protein kinases Pim-1 and Pim-2
belong to the same family of proto-oncogenes, with
partially redundant functions in IL-2 and IL-3 signaling
in vivo (81–83). While Pim-1 is a known STAT5 target
(10,41,84), regulation of Pim-2 expression by STAT5
remains elusive. We show here that IL-3 induction of Pim-
2 is diminished in STAT5A/B siRNA-transfected Ba/F3-b
cells. However, expression of both genes appears to be
diﬀerentially regulated by IL-3 in these cells. First, while
Pim-1 is induced as an early response gene (10) (Table 2),
Pim2 is a late response gene (Table 2 and data not shown).
Second, while IL-3 induction of Pim-1 is repressed by the
deacetylase inhibitor—and inhibitor of STAT5-mediated
transcription—TSA (10), induction of Pim-2 is not (data
not shown). In addition, no STAT5 binding was detected
within the Pim-2 gene in vivo, although four consensus
binding sites were found between positions ^1520 and ^
270 of the Pim-2 promoter. It remains, thus, unclear
whether Pim-2 is a direct target of STAT5, in contrast to
Pim-1. Collectively, although they belong to the same
family of proto-oncogenes, Pim-1 and Pim-2 regulation by
STAT5 appears to involve distinct mechanisms.
Surprisingly, IL-3 induction of the known STAT5
targets Id-1, c-Myc and Bcl-x was not diminished upon
siRNA-mediated STAT5A/B knockdown (Figure 2 and
Table 2), although all three genes were upregulated in Ba/
F3 cells expressing a constitutively active form of
STAT5A (designated 1
 6) (10,84), and IL-3-mediated
induction was inhibited by TSA (10). The fact that
STAT5A/B knockdown does not aﬀect expression of
these genes cannot be explained by compensatory eﬀects
of STAT3 (Figure 3), and thus suggests either that robust
IL-3-mediated STAT5-independent regulation of these
genes does not lead to reduced expression upon STAT5
knockdown, or that these genes are subject to an
alternative mechanism of transcriptional regulation by
STAT5. Interestingly, Id-1, c-Myc and Bcl-x bear
unconventional STAT5 binding site locations. STAT5
3814 Nucleic Acids Research, 2008, Vol. 36, No. 11binds within the ﬁrst intron of the Bcl-x gene and >4kb
downstream of the Id-1 gene (11,39,85). A preliminary
attempt to identify STAT5 binding within the proximal c-
Myc promoter in vivo was not successful (A.R., unpub-
lished data), suggesting that the STAT5 responsive
element might be located elsewhere. It is therefore likely
that transcriptional regulation by STAT5 through remote
regulatory elements involves an alternative mechanism,
possibly involving chromatin components and/or addi-
tional factors. In an attempt to explain how a 60%
reduction in STAT5 protein levels upon siRNA knock-
down does not inﬂuence expression of these genes, we can
already rule out that STAT5 is constitutively bound to
DNA even in the absence of IL-3 (7,39), since STAT5
binding on the Id-1 gene in vivo in unstimulated cells was
at background levels and was clearly induced in response
to IL-3 (Table 2 and data not shown). Alternatively, stable
STAT5-containing complexes might persist in the nucleus
of unstimulated cells, which could be recruited to DNA
upon IL-3 stimulation. Further investigations would be
necessary to address that complex question. In particular,
it would be interesting to explore STAT5 recruitment by
ChIP upon siRNA-mediated STAT5 knockdown.
The analysis of the newly identiﬁed and previously
characterized STAT5 DNA binding sites (Table 3) shows
that all elements consist of a tandem arrangement of at
least two consensus motifs [TTCNNNGAA or more
precisely TTCYNUGAA, in agreement with published
data (30)] or of one consensus plus at least one non-
consensus motifs (i.e. containing one mismatch), suggest-
ing that cooperation through STAT5 tetramerization
might be essential for eﬃcient transcriptional activation
in vivo (32,34–37). One exception was the C3ar1 gene,
lacking consensus binding sites but encompassing a cluster
of seven non-consensus motifs that eﬃciently bound
STAT5 in vivo. Interestingly, Nelson et al. [see supplemen-
tary materials (39)] recently identiﬁed novel STAT5 target
genes presenting a similar conﬁguration. This observation
suggests that the lack of consensus sequence can be
compensated by the presence of multiple non-optimal
binding sites which might allow cooperative binding of
STAT5. The identiﬁcation of the TNFRSF13b STAT5
binding sites within the second intron (Table 3) conﬁrms a
recent ChIP-based genome-wide survey showing that
STAT5 binding sites are often located within introns
(39), a characteristic also shared by the STAT5 target gene
Bcl-x (85). Further studies (EMSA, reporter assays) will be
needed to investigate the functionality of these newly
identiﬁed STAT5 binding elements.
Out of the STAT5-regulated genes tested by ChIP, ﬁve
showed no detectable binding within the region investi-
gated (Table 2). An absence of binding could signify either
that the binding site is located outside the investigated
region (^6000/polyA), as such elements can be located up
to 200kb downstream the transcription start site (11,86),
or that it is mediated through interaction with other
transcription factors (87) or more likely that regulation of
gene expression by STAT5 is indirect. It is more likely that
the late response genes, for which no STAT5 binding sites
were identiﬁed, such as Pim-2, IL-2Rb, Ryk and Slfn2, are
indirectly regulated by STAT5. In support to that
proposition, these genes did not show the expected
expression pattern either in response to TSA (Pim-2, see
above) or in the Ba/F3-1
 6 cell line expressing a
constitutively active form of STAT5A (IL-2Rb, Ryk and
Slfn2, data not shown). Alternatively, we cannot exclude
that the time point chosen to perform the ChIP assay
(45min of IL-3 stimulation) did not allow signiﬁcant
detection of STAT5 recruitment.
Table 2 summarizes the results of our study. It did not
reveal a clear correlation between position of the binding
site, potency of DNA binding, speciﬁcity toward STAT5A
or STAT5B, or expression proﬁle (early versus late
response genes). This demonstrates that transcriptional
regulation by STAT5 in vivo is complex, probably involv-
ing local chromatin structure and additional factors, likely
responsible for the speciﬁcity of gene regulation. On the
other hand, and as predicted, a correlation was found
between the degree of inhibition in the STAT5A/B
knockdown and the speciﬁc requirement for ‘STAT5A
or STAT5B’ versus ‘STAT5A and STAT5B’. While the
expression of genes that were redundantly regulated by
STAT5A and STAT5B (Table 2, genes numbered 1–10)
was inhibited to 55% in average in the double knock-
down, the genes that were dependent on the presence of
only one or of both STAT5 proteins (Table 2, genes
numbered 11–21) were more dramatically aﬀected in the
double knockdown (78% inhibition in average). Again,
exceptions were observed, emphasizing the existence of
additional levels of regulation.
We identiﬁed three novel STAT5 target genes, namely
TNFRSF13b, MKP-1 and C3ar1, that show distinct
expression proﬁles in response to IL-3, distinct require-
ments for STAT5A and STAT5B, and distinct STAT5
DNA binding characteristics (Tables 2 and 3). All the
three genes have been previously associated with tumor-
igenesis (63–66,73). TNFRSF13b encodes the transmem-
brane activator and CAML interactor (TACI) protein and
is a receptor for TNFSF13/APRIL and TNFSF13B/
TALL1/BAFF/BLYS ligands. It is involved in the
stimulation of B and T cell function and the regulation
of humoral immunity (60,62,64,88–90). Defect in
TNFRSF13b is associated with lymphoid and non-
lymphoid malignancies, autoimmune disorders and is a
cause of immunodeﬁciencies, such as common variable
immunodeﬁciency (CVID), and immunoglobulin A deﬁ-
ciency (IgAD) (59–64). MKP-1 is a dual speciﬁcity
phosphatase essential for the dephosphorylation of MAP
kinases p38 and JNK (91). MKP-1 acts as a negative
regulator of the synthesis of proinﬂammatory cytokines
in vivo, hence playing a pivotal role in the feedback control
of the innate immune response (91), a function also shared
by the STAT5 target gene SOCS-1 (92). MKP-1 was
found overexpressed in a number of human cancer tissues
or cell lines (65–67) and to contribute to tumorigenesis
in pancreatic cancer and non-small-cell lung cancer
(NSCLC) (65,66). We showed here that C3ar1 is upregu-
lated in renal cancer and melanoma. Whether this newly
described cancer association is the consequence of STAT5
constitutive activation remains to be established, but,
together with its previous association with mutant FLT3-
mediated CN-AML (73), it raises the possibility that
Nucleic Acids Research, 2008, Vol. 36, No. 11 3815C3ar1 overexpression is involved in tumorigenesis in
STAT5-associated malignancies. Our data demonstrate
the eﬃciency of an approach combining gene expression
proﬁling, ChIP and cancer panel expression analysis to
identify potential STAT5-dependent oncogenes.
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